Bifonazole cream: once-a-day application every second day in tinea cruris and tinea corporis.
The efficacy and local tolerance of Bay h 4502 1% cream were investigated in Tinea corporis and Tinea cruris. This biometrically designed, noncontrolled study was carried out in 32 patients (27 males and 5 females). The mean values of age, height and body weight were 25 years, 160.7 cm and 65.7 kg. Bay h 4502 1% cream was applied once daily every second day for 2 weeks. Mycological and clinical controls were carried out 1 week after starting therapy as well as 3 days and 2 weeks after the end of therapy. The direct microscopic examination was negative in 28/28 patients (100%) after the end of therapy as well as at the follow-up examination in 32/32 patients (100%). No pathogenic organisms were seen in 20/28 patients (71%) at the end of therapy and in 28/32 patients (88%) at the follow-up control. The overall success rate shows an analogous picture: 'very good' and 'good' was assessed for 26 patients (81%) at the end of therapy. In 50% of patients the onset of improvement occurred within 5 days after start of treatment, and between the 6th and 12th day in a further 47%. The local tolerance was good. The results obtained show that there is no difference by this study in comparison with previous studies with a treatment once daily every day. This gives additional safety by minimizing the risk of failures in all those patients sometimes not following strictly doctor's advise.
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D014005:Tinea / Q000188:drug therapy*
D000935:Antifungal Agents; D007093:Imidazoles; C036596:bifonazole